SCHEDULE 13G/A: Polar Asset Management Partners Divests Entire Stake in AEON Biopharma, Reports Zero Beneficial Ownership

Polar Asset Management Partners Inc. has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in AEON Biopharma Inc.'s Class A Common Stock as of March 31, 2025.

Summary

• Polar Asset Management Partners Inc., an investment advisor based in Ontario, Canada, has filed an Amendment No. 2 to its Schedule 13G for AEON Biopharma Inc.
• The filing states that as of March 31, 2025, Polar Asset Management Partners Inc. holds 0% beneficial ownership of AEON Biopharma Inc.'s Class A Common Stock.
• This indicates that the firm no longer possesses any sole or shared voting or dispositive power over AEON Biopharma shares.
• The reporting person certified that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The sentiment is negative as a significant institutional investor, Polar Asset Management Partners Inc., has fully divested its stake in AEON Biopharma Inc., reducing its beneficial ownership to 0%.

Negatives

• Polar Asset Management Partners Inc., a significant investment advisor, has divested its entire beneficial ownership in AEON Biopharma Inc., reducing its stake from a previously reported level to 0% as of March 31, 2025.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership report.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine disclosure of an institutional investor's ownership stake. The complete divestment by Polar Asset Management Partners Inc. could signal a change in their investment thesis regarding AEON Biopharma or the broader biotechnology sector, potentially reflecting a shift in capital allocation or a negative outlook on the company's prospects.

Comparison to Industry Standards

• This document does not provide financial or operational results that can be compared to industry benchmarks or specific comparable companies. It solely reports a change in beneficial ownership by an investment firm.

Stakeholder Impact

• Shareholders of AEON Biopharma Inc. may perceive the complete divestment by Polar Asset Management Partners Inc. as a negative indicator, potentially leading to decreased investor confidence or share price pressure.

Key Dates

Recommendation

Keywords

AEON Biopharma Inc., Polar Asset Management Partners Inc., Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Advisor, Divestment, SEC Filing